Sign in with your email address username.


[Comment] Interim results from a phase 3 Ebola vaccine study in Guinea

In today’s Lancet, Ana Maria Henao-Restrepo and an international collaboration that included WHO, Médecins Sans Frontières, Guinean authorities, and others report1 the interim results of the Ebola, ça Suffit (“Ebola, that’s enough”) trial. This trial was done in Guinea and was designed to test the safety and efficacy of rVSV-ZEBOV, a live recombinant vesicular stomatitis virus-vectored vaccine that expresses Zaire Ebola virus surface glycoprotein. The novel study design was based on the ring-vaccination strategy used in the final stages of the smallpox eradication campaign, ensuring that participants were at appreciable risk of Ebola virus infection even though the epidemic was beginning to wane.